For the quarter ended September 2025, 10x Genomics (TXG) reported revenue of $149 million, down 1.8% over the same period last year. EPS came in at -$0.22, compared to -$0.30 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $142.39 million, representing a surprise of +4.64%. The company delivered an EPS surprise of +18.52%, with the consensus EPS estimate being -$0.27.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Services: $8.13 million versus $7.86 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +27.1% change.
- Revenues- Instruments: $12 million versus the three-analyst average estimate of $14.06 million. The reported number represents a year-over-year change of -37%.
- Revenues- Instruments- Chromium: $4.93 million versus $5.36 million estimated by three analysts on average.
- Revenues- Consumables- Chromium: $92.52 million versus the three-analyst average estimate of $85.29 million.
- Revenues- Consumables- Spatial: $35.37 million compared to the $35.06 million average estimate based on three analysts.
- Revenues- Consumables: $127.89 million compared to the $120.35 million average estimate based on three analysts. The reported number represents a change of +1.3% year over year.
- Revenues- Instruments- Spatial: $7.07 million compared to the $8.71 million average estimate based on three analysts.
View all Key Company Metrics for 10x Genomics here>>>
Shares of 10x Genomics have returned +11.8% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
10x Genomics (TXG): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
